Arrowstreet Capital’s 10x Genomics TXG Stock Holding History

Arrowstreet Capital’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.62M	Buy	+224,785	New	+$5.89M	﹤0.01%	1130
2026 Q1	–	Sell	-15,680	Closed	-$256K	–	2100
2025 Q4	$256K	Buy	+15,680	New	+$237K	﹤0.01%	1759
2025 Q3	–	Sell	-123,604	Closed	-$1.43M	–	2116
2025 Q2	$1.43M	Buy	123,604 +107,023	+645%	+$976K	﹤0.01%	1529
2025 Q1	$145K	Buy	+16,581	New	+$209K	﹤0.01%	1754
2022 Q3	–	Sell	-5,846	Closed	-$265K	–	1465
2022 Q2	$265K	Buy	+5,846	New	+$303K	﹤0.01%	1139
2021 Q4	–	Sell	-27,100	Closed	-$3.94M	–	1733
2021 Q3	$3.94M	Buy	27,100 +4,500	+20%	+$773K	﹤0.01%	986
2021 Q2	$4.43M	Buy	+22,600	New	+$4.09M	0.01%	1108
2021 Q1	–	Sell	-2,600	Closed	-$368K	–	2544
2020 Q4	$368K	Sell	2,600 -41,166	-94%	-$5.97M	﹤0.01%	2078
2020 Q3	$5.46M	Sell	43,766 -32,900	-43%	-$3.45M	0.01%	1109
2020 Q2	$6.85M	Buy	+76,666	New	+$5.97M	0.01%	933

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital's TXG Position: Q2 2026 in Review

Arrowstreet Capital opened a new position in 10x Genomics (TXG) in Q2 2026: 224,785 shares worth $8.62M. The stake represents ﹤0.01% of the portfolio and ranks #1130 among its holdings. This is a return to the name: Arrowstreet Capital previously reported a position in TXG as recently as Q4 2025.

Arrowstreet Capital first reported a position in TXG in Q2 2020 and has held it in 10 quarters since. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Arrowstreet Capital held 224,785 shares of 10x Genomics worth $8.62M as of Q2 2026.
10x Genomics was a new Arrowstreet Capital position in Q2 2026.
10x Genomics made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1130 holding.
Arrowstreet Capital first reported a position in 10x Genomics in Q2 2020 and has held it in 10 quarters since.
393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.